TranSynergy: Mechanism-Driven Interpretable Deep Neural Network for the Synergistic Prediction and Pathway Deconvolution of Drug Combinations

Author:

Liu QiaoORCID,Xie Lei

Abstract

AbstractMotivationDrug combinations have demonstrated great potential in cancer treatments. They alleviate drug resistance and improve therapeutic efficacy. With the fast-growing number of anti-cancer drugs, the experimental investigation of all drug combinations is costly and time-consuming. Computational techniques can improve the efficiency of drug combination screening. Despite recent advances in applying machine learning to synergistic drug combinations prediction, several challenges remain. First, the performance of existing methods is suboptimal. There is still much space for improvement. Second, biological knowledge has not been fully incorporated into the model. Finally, many models are lack of interpretability, limiting their clinical applications.ResultsWe develop a knowledge-enabled and self-attention boosted deep learning model, TranSynergy, to improve the performance and interpretability of synergistic drug combinations prediction. TranSynergy is well designed such that cellular effect of drug actions can be explicitly modeled through cell-line gene dependency, gene-gene interaction, and genome-wide drug-target interaction. A novel Shapley Additive Gene Set Enrichment Analysis (SA-GSEA) method is developed to deconvolute biological pathways that contribute to the synergistic drug combination and improve model interpretability. Extensive benchmark studies demonstrate that TranSynergy significantly outperforms the state-of-the-art method, suggesting the potential of mechanism-driven machine learning. Novel pathways that are associated with the synergistic combinations are revealed and supported by experimental evidence. They may provide new insights into identifying biomarkers for precision medicine and discovering new anti-cancer therapies. Several new synergistic drug combinations are predicted with high confidence for ovarian cancer which has few treatment options.AvailabilityThe code is available at https://github.com/qiaoliuhub/drug_combinationContactlxie@iscb.org

Publisher

Cold Spring Harbor Laboratory

Reference82 articles.

1. New anticancer agents: recent developments in tumor therapy;Anticancer Res,2012

2. Biological representation of chemicals using latent target interaction profile;BMC Bioinformatics,2019

3. Bahdanau, D. , Cho, K. and Bengio, Y. Neural Machine Translation by Jointly Learning to Align and Translate. 2014.

4. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

5. Co‐targeting the PI3K/ mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3